Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 7/2016

22.03.2016 | Original Article

Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment

verfasst von: Kun-Ju Lin, Ing-Tsung Hsiao, Jung-Lung Hsu, Chin-Chang Huang, Kuo-Lun Huang, Chia-Ju Hsieh, Shiaw-Pyng Wey, Tzu-Chen Yen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated dual-phase 18F-florbetapir (AV-45/Amyvid) PET imaging for the concomitant detection of brain perfusion deficits and beta-amyloid deposition in patients with Alzheimer’s disease (AD) and amnestic mild cognitive impairment (MCI), and in cognitively healthy controls (HCs).

Methods

A total of 82 subjects (24 AD patients, 44 MCI patients and 14 HCs) underwent both dual-phase 18F-AV-45 PET and MRI imaging. Dual-phase dynamic PET imaging consisted of (1) five 1-min scans obtained 1 – 6 min after tracer injection (perfusion 18F-AV-45 imaging, pAV-45), and (2) ten 1-min scans obtained 50 – 60 min after tracer injection (amyloid 18F-AV-45 imaging). Amyloid-negative MCI/AD patients were excluded. Volume of interest analysis and statistical parametric mapping of pAV-45 and 18F-AV-45 images were performed to investigate the perfusion deficits and the beta-amyloid burden in the three study groups. The associations between Mini-Mental State Examination (MMSE) scores and global perfusion deficits and amyloid deposition were investigated with linear and segmental linear correlation analyses.

Results

HCs generally had normal pAV-45 findings, whereas perfusion deficits were evident in the hippocampus, and temporal, parietal and middle frontal cortices in both MCI and AD patients. The motor-sensory cortex was relatively preserved. MMSE scores in the entire study cohort were significantly associated with the degree of perfusion impairment as assessed by pAV-45 imaging (r = 0.5156, P < 0.0001). 18F-AV-45 uptake was significantly higher in AD patients than in the two other study groups. However, the correlation between MMSE scores and 18F-AV-45 uptake in MCI patients was more of a binary phenomenon and began in MCI patients with MMSE score 23.14 when 18F-AV-45 uptake was higher and MMSE score lower than in patients with early MCI. Amyloid deposition started in the precuneus and the frontal and temporal regions in early MCI, ultimately reaching the maximum burden in advanced MCI.

Conclusion

Our results indicate that brain perfusion deficits and beta-amyloid deposition in AD follow different trajectories that can be successfully traced using dual-phase 18F-AV-45 PET imaging.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9.CrossRefPubMedPubMedCentral McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.CrossRefPubMed Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.CrossRefPubMed
3.
Zurück zum Zitat Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent – a pilot study. Nucl Med Biol. 2010;37:497–508.CrossRefPubMed Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent – a pilot study. Nucl Med Biol. 2010;37:497–508.CrossRefPubMed
4.
Zurück zum Zitat Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251–9.CrossRefPubMed Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 2009;50:1251–9.CrossRefPubMed
5.
Zurück zum Zitat Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.CrossRefPubMed Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.CrossRefPubMed
6.
Zurück zum Zitat Jagust WJ, Friedland RP, Budinger TF. Positron emission tomography with [18F]fluorodeoxyglucose differentiates normal pressure hydrocephalus from Alzheimer-type dementia. J Neurol Neurosurg Psychiatry. 1985;48:1091–6.CrossRefPubMedPubMedCentral Jagust WJ, Friedland RP, Budinger TF. Positron emission tomography with [18F]fluorodeoxyglucose differentiates normal pressure hydrocephalus from Alzheimer-type dementia. J Neurol Neurosurg Psychiatry. 1985;48:1091–6.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Smith FW, Besson JA, Gemmell HG, Sharp PF. The use of technetium-99m-HM-PAO in the assessment of patients with dementia and other neuropsychiatric conditions. J Cereb Blood Flow Metab. 1988;8:S116–22.CrossRefPubMed Smith FW, Besson JA, Gemmell HG, Sharp PF. The use of technetium-99m-HM-PAO in the assessment of patients with dementia and other neuropsychiatric conditions. J Cereb Blood Flow Metab. 1988;8:S116–22.CrossRefPubMed
8.
Zurück zum Zitat Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119–28.CrossRefPubMedPubMedCentral Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119–28.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86.CrossRefPubMedPubMedCentral Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578–86.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One. 2012;7:e47905.CrossRefPubMedPubMedCentral Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One. 2012;7:e47905.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–20.CrossRefPubMed Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–20.CrossRefPubMed
12.
Zurück zum Zitat Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393–400.CrossRefPubMed Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393–400.CrossRefPubMed
13.
Zurück zum Zitat Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46:936–44.PubMed Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46:936–44.PubMed
14.
Zurück zum Zitat Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U, et al. Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med. 2007;48:1207–15.CrossRefPubMed Treyer V, Streffer J, Wyss MT, Bettio A, Ametamey SM, Fischer U, et al. Evaluation of the metabotropic glutamate receptor subtype 5 using PET and 11C-ABP688: assessment of methods. J Nucl Med. 2007;48:1207–15.CrossRefPubMed
15.
Zurück zum Zitat Farid K, Hong YT, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, et al. Early-phase 11C-PiB PET in amyloid angiopathy-related symptomatic cerebral hemorrhage: potential diagnostic value? PLoS One. 2015;10:e0139926.CrossRefPubMedPubMedCentral Farid K, Hong YT, Aigbirhio FI, Fryer TD, Menon DK, Warburton EA, et al. Early-phase 11C-PiB PET in amyloid angiopathy-related symptomatic cerebral hemorrhage: potential diagnostic value? PLoS One. 2015;10:e0139926.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Gur RC, Ragland JD, Reivich M, Greenberg JH, Alavi A, Gur RE. Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state. Cereb Cortex. 2009;19:375–82.CrossRefPubMedPubMedCentral Gur RC, Ragland JD, Reivich M, Greenberg JH, Alavi A, Gur RE. Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state. Cereb Cortex. 2009;19:375–82.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Murase K, Tanada S, Fujita H, Sakaki S, Hamamoto K. Kinetic behavior of technetium-99m-HMPAO in the human brain and quantification of cerebral blood flow using dynamic SPECT. J Nucl Med. 1992;33:135–43.PubMed Murase K, Tanada S, Fujita H, Sakaki S, Hamamoto K. Kinetic behavior of technetium-99m-HMPAO in the human brain and quantification of cerebral blood flow using dynamic SPECT. J Nucl Med. 1992;33:135–43.PubMed
18.
Zurück zum Zitat Wong CY, Thie J, Gaskill M, Ponto R, Hill J, Tian HY, et al. A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging. BMC Nucl Med. 2006;6:4.CrossRefPubMedPubMedCentral Wong CY, Thie J, Gaskill M, Ponto R, Hill J, Tian HY, et al. A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging. BMC Nucl Med. 2006;6:4.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Chen Y, Wolk D, Reddin J, Korczykowski M, Martinez P, Musiek E, et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology. 2011;77:1977–85.CrossRefPubMedPubMedCentral Chen Y, Wolk D, Reddin J, Korczykowski M, Martinez P, Musiek E, et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology. 2011;77:1977–85.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Musiek ES, Chen Y, Korczykowski M, Saboury B, Martinez PM, Reddin JS, et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement. 2012;8:51–9.CrossRefPubMedPubMedCentral Musiek ES, Chen Y, Korczykowski M, Saboury B, Martinez PM, Reddin JS, et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement. 2012;8:51–9.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early [11C]PIB frames and [18F]FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173–9.PubMedPubMedCentral Rostomian AH, Madison C, Rabinovici GD, Jagust WJ. Early [11C]PIB frames and [18F]FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med. 2011;52:173–9.PubMedPubMedCentral
22.
Zurück zum Zitat Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, et al. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One. 2013;8:e58974.CrossRefPubMedPubMedCentral Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, et al. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One. 2013;8:e58974.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–6.CrossRefPubMed Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–6.CrossRefPubMed
24.
Zurück zum Zitat Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92.CrossRefPubMed Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92.CrossRefPubMed
25.
Zurück zum Zitat American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. Washington, DC: American Psychiatric Association. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. Washington, DC: American Psychiatric Association.
26.
Zurück zum Zitat Lin RT, Lai CL, Tai CT, Liu CK, Yen YY, Howng SL. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Neurol Sci. 1998;160:67–75.CrossRefPubMed Lin RT, Lai CL, Tai CT, Liu CK, Yen YY, Howng SL. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Neurol Sci. 1998;160:67–75.CrossRefPubMed
27.
Zurück zum Zitat Liu CK, Lin RT, Chen YF, Tai CT, Yen YY, Howng SL. Prevalence of dementia in an urban area in Taiwan. J Formos Med Assoc. 1996;95:762–8.PubMed Liu CK, Lin RT, Chen YF, Tai CT, Yen YY, Howng SL. Prevalence of dementia in an urban area in Taiwan. J Formos Med Assoc. 1996;95:762–8.PubMed
28.
Zurück zum Zitat McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–44.CrossRefPubMed McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–44.CrossRefPubMed
29.
Zurück zum Zitat Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, et al. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot. 2010;68:2293–7.CrossRefPubMed Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, et al. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot. 2010;68:2293–7.CrossRefPubMed
31.
Zurück zum Zitat Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage. 1995;2:89–101.CrossRefPubMed Mazziotta JC, Toga AW, Evans A, Fox P, Lancaster J. A probabilistic atlas of the human brain: theory and rationale for its development. The International Consortium for Brain Mapping (ICBM). Neuroimage. 1995;2:89–101.CrossRefPubMed
32.
Zurück zum Zitat Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.CrossRefPubMed Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.CrossRefPubMed
33.
Zurück zum Zitat Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni G, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage Clin. 2015;7:34–42.CrossRefPubMedPubMedCentral Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni G, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage Clin. 2015;7:34–42.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305:275–83.CrossRefPubMed Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305:275–83.CrossRefPubMed
35.
Zurück zum Zitat Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72–83.CrossRefPubMedPubMedCentral Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9:S72–83.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309.CrossRefPubMed Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309.CrossRefPubMed
37.
Zurück zum Zitat Del Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Maggiore L, et al. Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study. Eur J Nucl Med Mol Imaging. 2008;35:1357–66.CrossRefPubMed Del Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Maggiore L, et al. Individual cerebral metabolic deficits in Alzheimer’s disease and amnestic mild cognitive impairment: an FDG PET study. Eur J Nucl Med Mol Imaging. 2008;35:1357–66.CrossRefPubMed
38.
Zurück zum Zitat Silverman DH, Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin North Am. 2005;43:67–77.CrossRefPubMed Silverman DH, Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin North Am. 2005;43:67–77.CrossRefPubMed
39.
Zurück zum Zitat Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, et al. Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease. Brain Imaging Behav. 2012;6:568–83.CrossRefPubMedPubMedCentral Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, et al. Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease. Brain Imaging Behav. 2012;6:568–83.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol. 2006;59:673–81.CrossRefPubMed Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol. 2006;59:673–81.CrossRefPubMed
41.
Zurück zum Zitat Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18.CrossRefPubMedPubMedCentral Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Shokouhi S, Claassen D, Kang H, Ding Z, Rogers B, Mishra A, et al. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med. 2013;54:1564–9.CrossRefPubMedPubMedCentral Shokouhi S, Claassen D, Kang H, Ding Z, Rogers B, Mishra A, et al. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med. 2013;54:1564–9.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Alexopoulos P, Sorg C, Forschler A, Grimmer T, Skokou M, Wohlschlager A, et al. Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer’s disease measured by pulsed arterial spin labeling MRI. Eur Arch Psychiatry Clin Neurosci. 2012;262:69–77.CrossRefPubMed Alexopoulos P, Sorg C, Forschler A, Grimmer T, Skokou M, Wohlschlager A, et al. Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer’s disease measured by pulsed arterial spin labeling MRI. Eur Arch Psychiatry Clin Neurosci. 2012;262:69–77.CrossRefPubMed
44.
Zurück zum Zitat Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage. 1995;2:148–56.CrossRefPubMed Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage. 1995;2:148–56.CrossRefPubMed
45.
Zurück zum Zitat Bozzao A, Floris R, Baviera ME, Apruzzese A, Simonetti G. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol. 2001;22:1030–6.PubMed Bozzao A, Floris R, Baviera ME, Apruzzese A, Simonetti G. Diffusion and perfusion MR imaging in cases of Alzheimer's disease: correlations with cortical atrophy and lesion load. AJNR Am J Neuroradiol. 2001;22:1030–6.PubMed
46.
Zurück zum Zitat Shimizu S, Zhang Y, Laxamana J, Miller BL, Kramer JH, Weiner MW, et al. Concordance and discordance between brain perfusion and atrophy in frontotemporal dementia. Brain Imaging Behav. 2010;4:46–54.CrossRefPubMedPubMedCentral Shimizu S, Zhang Y, Laxamana J, Miller BL, Kramer JH, Weiner MW, et al. Concordance and discordance between brain perfusion and atrophy in frontotemporal dementia. Brain Imaging Behav. 2010;4:46–54.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168–74.CrossRefPubMed Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in “normal” aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168–74.CrossRefPubMed
48.
Zurück zum Zitat Pearl GS. Diagnosis of Alzheimer's disease in a community hospital-based brain bank program. South Med J. 1997;90:720–2.CrossRefPubMed Pearl GS. Diagnosis of Alzheimer's disease in a community hospital-based brain bank program. South Med J. 1997;90:720–2.CrossRefPubMed
49.
Zurück zum Zitat Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63:665–72.CrossRefPubMed Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 2006;63:665–72.CrossRefPubMed
Metadaten
Titel
Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment
verfasst von
Kun-Ju Lin
Ing-Tsung Hsiao
Jung-Lung Hsu
Chin-Chang Huang
Kuo-Lun Huang
Chia-Ju Hsieh
Shiaw-Pyng Wey
Tzu-Chen Yen
Publikationsdatum
22.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3359-8

Weitere Artikel der Ausgabe 7/2016

European Journal of Nuclear Medicine and Molecular Imaging 7/2016 Zur Ausgabe